The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Abstract
Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 10 9 /L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 × 10 9 /L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) –weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95% CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95% CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95% CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31% v 12%; HR, 3.3; 95% CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationMyelofibrosis with Myeloid Metaplasia
Tefferi, A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421706 · Cited by 740
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationTefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationTefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationPathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Self-citationTefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationBarosi, G., Viarengo, G., Pecci, A., Rosti, V., Piaggio, G., Marchetti, M., & Frassoni, F. (2001) · Blood · doi:10.1182/blood.v98.12.3249 · Cited by 223
Cited by
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationTefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationTefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
Self-citationBarbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4886 · Cited by 552
Self-citationTefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 548
Self-citationfor the COMFORT-I investigators, Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0417-z · Cited by 431
Spivak, J. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1406186 · Cited by 404
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5818 · Cited by 399
Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.169 · Cited by 348
Self-citationMyeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Self-citationTefferi, A., & Vainchenker, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8711 · Cited by 327
Self-citationA Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Self-citationMesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26050 · Cited by 315
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 310
Self-citationGIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0107-z · Cited by 306
Self-citationVerstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J.-J., Cervantes, F., Harrison, C. N., Paquette, R., Sun, W., Naim, A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0527-7 · Cited by 305
Self-citationPrimary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Self-citationGelsi-Boyer, V., Brecqueville, M., Devillier, R., Murati, A., Mozziconacci, M.-J., & Birnbaum, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-12 · Cited by 278
Tefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., Belachew, A. A., Pancrazzi, A., Wassie, E. A., Ketterling, R. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.57 · Cited by 277
Self-citationKröger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., Rambaldi, A., Mesa, R., Tefferi, A., Griesshammer, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.233 · Cited by 277
Self-citationEZH2 mutational status predicts poor survival in myelofibrosis
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A. V., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363424 · Cited by 262
Self-citationOne Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al-Kali, A., Ketterling, R. P., Hanson, C. A., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.001 · Cited by 260
Self-citationDiagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Rumi, E., & Cazzola, M. (2017) · Blood · doi:10.1182/blood-2016-10-695957 · Cited by 258
Vaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., & Tefferi, A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23295 · Cited by 149
Self-citationVerstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0901 · Cited by 41
Metadata
- Authors
- Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F., & Tefferi, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-01
- Volume
- 29
- Issue
- 4
- Pages
- 392-397
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2049965335
- Cited by
- 1,055
- References
- 19
- FWCI
- 21.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.